logo-loader
viewImugene Ltd

Imugene obtains FDA guidance for KEY-Vaxx immunotherapy clinical development plan

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong updates Proactive Investors on the clinical-stage immuno-oncology company’s development of its KEY-Vaxx cancer vaccine.
 
The company had a pre-investigational new drug meeting with the US Food and Drug Administration (FDA) to obtain regulatory guidance and agreement on the preclinical chemistry and controls for KEY-Vaxx’s clinical development plan. 
 
“They approved everything we wanted to do and even ratcheted us back from doing some of the tests because it wasn’t necessary,” says Chong. 
 
She continues, “given that the FDA fully approved our pre-clinical plan, it really bodes well for the safety of this drug.”

Quick facts: Imugene Ltd

Price: 0.045 AUD

ASX:IMU
Market: ASX
Market Cap: $162.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

5 days, 15 hours ago

2 min read